Searchable abstracts of presentations at key conferences in endocrinology

ea0099rc2.3 | Rapid Communications 2: Calcium and Bone | Part I | ECE2024

Metformin prevents glucocorticoid-induced bone resorption in healthy subjects

Pfammatter Stephanie , Lisa Zanetti , Thierry Susanne , Meier Christian , Seelig Eleonora

Background: Glucocorticoids are crucial for treating various medical conditions due to their beneficial immunosuppressive effects. However, glucocorticoids also carry a high risk for osteoporosis. Notably, within just a few months of glucocorticoid therapy, bone density can be significantly reduced, and up to 5% of patients undergoing such treatment may experience fractures. There is promising evidence from preclinical studies and observations in patients with type 2 diabetes ...

ea0090rc10.5 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

Metformin counteracts adverse metabolic effects of glucocorticoids in healthy subjects

Thierry Susanne , Peterson Caspar Joyce , Delko Tarik , Iten Vasco , Epstein Michael , Kuhne Michael , Meyer-Zurn Christine , Seelig Eleonora

Background: Glucocorticoids are powerful anti-infla mmatory drugs. However, metabolic side effects are common and limit their long-term use. Furthermore, the underlying mechanisms of adverSemetabolic effects are not well known, and this lack of knowledge results in poor treatment. We have previously shown that the antidiabetic drug metformin prevents glucocorticoid-induced metabolic effects in older, sick patients. Here, we investigate metformin in a young and healthy populati...